US medical groups fill CDC policy gap with independent 2026-27 respiratory vaccine recommendations

Leading U.S. medical organizations have issued coordinated recommendations for influenza, COVID-19 and respiratory syncytial virus immunization, creating an unusual parallel source of national vaccine guidance as the traditional federal recommendation process remains unsettled. The American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists and Infectious Diseases Society of America released guidance for their respective patient populations, supported by an independent evidence review developed through the Vaccine Integrity Project and American Medical Association. The recommendations arrive as updated COVID-19 vaccines begin reaching pharmacies and this year’s flu campaign gets underway, with doctors attempting to provide consistent guidance before respiratory illnesses typically accelerate during the fall and winter. The development marks a significant change in U.S. public-health governance because recommendations that historically flowed primarily through the Centers for Disease Control and Prevention and its advisory committee are now being supplemented by an organized medical-professional framework.

The medical groups say the objective is to reduce confusion rather than create a competing regulatory authority. Their recommendations do not replace Food and Drug Administration approvals or legally bind states, insurers or healthcare providers, but professional guidelines can strongly influence how physicians advise patients and how health systems approach immunization. The divergence is most visible around COVID-19, where current FDA approvals focus primarily on older adults and younger people with underlying risk factors while several medical organizations recommend vaccination for broader populations. That difference could make the 2026-27 respiratory-virus season an important test of what happens when federal regulators and major professional societies no longer provide Americans with a single, closely aligned vaccination framework.

Vaccine guidance traditionally led by CDC is increasingly being supplemented by medical societies

For decades, the CDC’s Advisory Committee on Immunization Practices has played a central role in determining how vaccines are recommended in the United States. The committee reviews evidence on disease burden, vaccine effectiveness, safety and cost before making recommendations that influence clinical practice, state programs and insurance coverage.

That process has become considerably more complicated following extensive changes to federal vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr. A federal judge in March blocked important elements of the administration’s attempt to alter childhood vaccine recommendations and ruled that changes involving the advisory process likely violated federal procedural requirements, leaving the committee’s current structure caught in continuing litigation.

The CDC had not issued equivalent new fall guidance when the medical organizations announced their recommendations, although its website continued directing clinicians toward previous influenza guidance. Professional organizations consequently decided to publish their own recommendations before the beginning of the main respiratory season rather than wait for the federal process to become clearer.

The American Academy of Family Physicians said its recommendations were coordinated with pediatric, obstetric and infectious-disease organizations through the Vaccine Integrity Project. That coordination gives physicians across several specialties a common evidence base even when the recommendations differ somewhat depending on age, pregnancy status or medical risk.

Independent review examined nearly 300 studies on COVID-19, influenza and RSV protection

The new recommendations are supported by evidence reviews led by the University of Minnesota-based Vaccine Integrity Project. Researchers evaluated 299 eligible studies, primarily published between August 2025 and June 2026, covering the epidemiology, effectiveness and safety of U.S.-licensed influenza, COVID-19 and RSV immunizations.

The project concluded that immunization continues to provide meaningful protection against hospitalization, severe disease and death, although the degree of protection varies by virus, vaccine product, population and circulating strain. Researchers also examined updated safety evidence and reported no new safety concerns in comparative studies involving currently recommended immunizations.

The analyses were published in JAMA alongside a broader explanation of why the independent framework was created. Authors including representatives from the American Medical Association and Vaccine Integrity Project said disruptions involving the federal advisory system had created a need for another mechanism capable of reviewing new evidence and communicating recommendations to clinicians and the public.

That approach represents a notable institutional development. Medical associations have always produced clinical guidance, but jointly constructing a national respiratory-vaccine evidence framework at the same moment the CDC process is disputed gives those organizations a substantially more prominent public-policy role.

Doctors continue broad flu recommendations while first mRNA flu vaccine enters US market

Influenza represents the area of greatest agreement. The participating medical groups recommend seasonal flu vaccination for nearly everyone beginning at 6 months of age, while emphasizing the particularly high risk faced by older adults, pregnant women, young children and people with chronic medical conditions.

The recommendations arrive after two severe influenza seasons in which unusually large numbers of children died, with the majority of pediatric deaths occurring among children who had not been vaccinated. The independent evidence review found continued protection against serious outcomes, including a reduction in hospitalization among older adults.

The 2026 season also introduces a significant technological change. The FDA approved Moderna’s mFlusiva in August for adults aged 50 and older, making it the first messenger RNA-based seasonal influenza vaccine approved in the United States. Standard approval covers adults aged 50 to 64, while use among people 65 and older received accelerated approval based on immune-response evidence and remains subject to additional confirmatory research.

The product gives Moderna a potentially important new market beyond COVID-19 vaccines while testing whether the mRNA platform can compete with established influenza technologies. The medical groups are not recommending that eligible patients delay vaccination while seeking a specific product, however, particularly for older adults for whom several enhanced influenza vaccine options already exist.

COVID-19 guidance exposes the clearest divide between federal approvals and medical groups

COVID-19 produces the most visible policy difference. The FDA recently approved updated XFG-adapted vaccines primarily for adults aged 65 and older and younger people who have at least one medical condition increasing their risk of severe disease. Pfizer and BioNTech’s updated Comirnaty formulation, for example, is approved for adults 65 and older and eligible higher-risk people aged 5 through 64.

Professional societies are recommending broader access in several populations. The American Academy of Family Physicians recommends COVID-19 vaccination for adults, with particularly strong emphasis on older adults and people with risk factors, while the American Academy of Pediatrics recommends vaccination for all children aged 6 through 23 months and for older children at elevated risk. The pediatric group also supports making vaccination available to older children when parents want protection even if the child does not fall into a high-risk category.

Evidence reviews published alongside the recommendations found COVID-19 vaccination continued to reduce serious outcomes, including hospitalization, and identified no new safety concerns in the reviewed comparative evidence. Researchers stressed that vaccine protection against infection and mild illness can vary as the virus evolves, while protection against severe outcomes remains the principal public-health objective.

The divergence does not mean doctors can change FDA labeling. Instead, it creates a situation in which clinical organizations may recommend immunization more broadly than the populations specifically covered by current federal approval language, leaving physicians, pharmacies, insurers and state regulators to navigate the practical consequences.

RSV recommendations target infants, pregnant women and older adults facing highest risks

RSV has become the third major component of fall respiratory-virus planning as vaccines and preventive antibodies have expanded substantially during recent years. The virus typically causes mild cold-like illness in healthy adults but can produce serious lower-respiratory disease in infants, older adults and people with weakened immune systems.

The American Academy of Pediatrics recommends protection for infants entering their first RSV season unless adequate protection was provided through maternal vaccination during pregnancy. It also recommends immunization for certain children aged 8 through 19 months who remain at elevated risk for severe RSV disease.

Available infant protection includes long-acting monoclonal antibodies rather than conventional vaccines administered directly to very young babies. Maternal vaccination during pregnancy provides another pathway by allowing antibodies generated by the mother to protect the infant after birth.

The Vaccine Integrity Project’s review found RSV immunizations were associated with lower risks of severe disease and hospitalization. Researchers said updated evidence remained broadly consistent with previous safety findings while noting that effectiveness among older adults may decline in subsequent seasons, an issue that could influence future decisions about how frequently revaccination is needed.

Insurance coverage and pharmacy access could become critical tests of fragmented guidance

The policy differences matter partly because vaccine recommendations affect more than conversations between physicians and patients. Federal recommendations historically help determine insurance requirements, pharmacy protocols and state vaccination programs, creating a relatively standardized pathway from regulatory approval to widespread access.

Most private insurers have indicated that they intend to maintain coverage for fall respiratory vaccines through 2027, while Medicare continues covering recommended vaccinations. Access may nevertheless differ by state because pharmacy rules governing COVID-19 vaccinations vary, particularly for younger patients.

That creates a potential gap between a physician recommending a vaccine and a patient being able to receive it conveniently or without additional cost. If the federal advisory system remains unresolved for an extended period, employers, insurers, pharmacies and state governments may increasingly rely on professional medical organizations when deciding how to structure their own policies.

The situation could also have commercial consequences for Pfizer, BioNTech, Moderna, Sanofi and other vaccine manufacturers. Broader medical-society recommendations could support demand, while uncertainty over eligibility, insurance coverage or pharmacy rules could discourage uptake even when products are available.

Parallel vaccine guidance could permanently change how US public-health recommendations are produced

The immediate objective is preparing Americans for the approaching respiratory-virus season, but the institutional implications extend much further. The Vaccine Integrity Project was established in 2025 specifically because of concerns about instability in the traditional federal vaccine-policy process, and its collaboration with major medical organizations is now producing a functioning alternative evidence-review structure.

That structure does not possess the regulatory authority of the FDA or CDC. It can nevertheless become influential if physicians, hospitals, insurers and patients increasingly treat medical-society recommendations as an independent reference point when federal policies are disputed.

A lasting split would make U.S. vaccine policy more decentralized. Federal regulators could determine which products are approved, while professional societies provide separate clinical recommendations and states or insurers decide which framework to follow when setting access and coverage rules.

Whether that becomes permanent will depend partly on the outcome of continuing legal battles involving the federal advisory system and future decisions by the Trump administration. For the 2026-27 season, however, the shift has already occurred: Americans are entering fall with major medical organizations providing a coordinated vaccination framework outside the traditional CDC-led process.

Key takeaways from the new independent US vaccine recommendations

• Major U.S. medical organizations have issued coordinated 2026-27 guidance covering influenza, COVID-19 and RSV immunization.
• The initiative comes as the traditional CDC vaccine-advisory process remains unsettled by policy changes and continuing federal litigation.
• The Vaccine Integrity Project reviewed 299 studies and found continued protection against severe disease, hospitalization and death from respiratory viruses.
• Medical groups broadly agree that nearly everyone aged 6 months and older should receive seasonal influenza vaccination.
• Moderna’s mFlusiva becomes the first FDA-approved mRNA seasonal flu vaccine, providing a new option for adults aged 50 and older.
• COVID-19 produces the biggest divergence, with FDA approvals focused on older and higher-risk people while some medical groups recommend broader vaccination.
• Pediatric guidance recommends COVID-19 vaccination for infants aged 6 through 23 months and older children at increased risk, while allowing broader parental choice.
• RSV recommendations continue targeting infants, some higher-risk young children, pregnant women and older adults most vulnerable to severe disease.
• Separate professional guidance could affect pharmacy access, insurance decisions and vaccine demand if the federal recommendation process remains unresolved.
• The 2026-27 respiratory season may establish a lasting model in which professional medical societies play a larger independent role in national vaccine policy.